• SL Bio completed its business combination with Horizon Space Acquisition II, creating Cayman Islands holding company SL Science Holding.
• SL Science ordinary shares set to begin trading June 15, 2026 on Nasdaq Global Market under ticker SLBT.
• Deal implied equity valuation of about USD 5.57 billion for SL Bio; included a concurrent USD 7.8 million PIPE financing.
• Proceeds aimed at advancing gamma delta T cell “off-the-shelf” therapies toward clinical trials for solid tumors, including pancreatic and brain cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-073797), on June 15, 2026, and is solely responsible for the information contained therein.